This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
by Zacks Equity Research
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
BMYNegative Net Change ALKSNegative Net Change FOLDNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
by Ekta Bagri
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Nov 13, 2025
by Zacks Equity Research
Companies in The News Are: LEGN, ONON, PLTR, ALC
ALCNegative Net Change LEGNNegative Net Change PLTRNegative Net Change ONONPositive Net Change
biotechnology semiconductor
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
NVSNegative Net Change ANIPNegative Net Change ADMANegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
by Zacks Equity Research
Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology earnings medical pharmaceuticals
Alto Ingredients (ALTO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ALTOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
by Ahan Chakraborty
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
ALKSNegative Net Change FOLDNegative Net Change CRMDNegative Net Change IMVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
ANIPNegative Net Change ADMANegative Net Change EDITNegative Net Change ARQTNegative Net Change
biotechnology biotechs earnings gene-editing medical pharmaceuticals
4 Stocks With Recent Price Strength to Enhance Your Portfolio
by Nalak Das
Four stocks, CSTL, PRM, SABK and ATRO show recent gains, signaling potential momentum plays for investors in 2025.
ATROPositive Net Change SABKNegative Net Change CSTLNegative Net Change PRMNegative Net Change
aerospace basic-materials biotechnology finance
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
by Ahan Chakraborty
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kennametal (KMT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
KMTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
by Zacks Equity Research
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
BIIBPositive Net Change ALKSNegative Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
RHHBYPositive Net Change BMYNegative Net Change NVONegative Net Change PRTANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
LLYPositive Net Change NKTRNegative Net Change ANIPNegative Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
by Zacks Equity Research
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
REGNPositive Net Change ANIPNegative Net Change ACADNegative Net Change NTLANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Buy 5 Stocks With High ROE as Markets Wobble on AI Growth Concerns
by Supriyo Bose
As markets reel from AI valuation worries and economic jitters, cash-rich, high-ROE stocks like Corning and TE Connectivity stand out as strong picks.
GLWNegative Net Change TELNegative Net Change BBVANegative Net Change ZTONegative Net Change VICINegative Net Change
artificial-intelligence biotechnology cloud-computing communications finance reit tech-stocks
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
FOLDNegative Net Change CPRXPositive Net Change ANIPNegative Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
by Zacks Equity Research
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
ALKSNegative Net Change FOLDNegative Net Change CRMDNegative Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
FOLDNegative Net Change ANIPNegative Net Change ACADNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
by Zacks Equity Research
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
ALKSNegative Net Change FOLDNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for Nov 6, 2025
by Zacks Equity Research
Companies In The News Are: AMGN, EXEL, LITE, MCD.
AMGNNegative Net Change MCDPositive Net Change EXELNegative Net Change LITENegative Net Change
biotechnology communications restaurants
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
by Zacks Equity Research
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
RHHBYPositive Net Change ALKSNegative Net Change EXELNegative Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
by Zacks Equity Research
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
REGNPositive Net Change BEAMNegative Net Change FOLDNegative Net Change RARENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals